Th17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemia

dc.contributor.authorMehrotra, Purvi
dc.contributor.authorCollett, Jason A.
dc.contributor.authorGunst, Susan J.
dc.contributor.authorBasile, David P.
dc.contributor.departmentCellular and Integrative Physiology, School of Medicineen_US
dc.date.accessioned2019-07-30T17:46:12Z
dc.date.available2019-07-30T17:46:12Z
dc.date.issued2018-02-01
dc.description.abstractAcute kidney injury (AKI) is associated with high mortality rates and predisposes development of chronic kidney disease (CKD). Distant organ damage, particularly in the lung, may contribute to mortality in AKI patients. Animal models of AKI demonstrate an increase in pulmonary infiltration of lymphocytes and reveal an acute compromise of lung function, but the chronic effects of AKI on pulmonary inflammation are unknown. We hypothesized that in response to renal ischemia/reperfusion (I/R), there is a persistent systemic increase in Th17 cells with potential effects on pulmonary structure and function. Renal I/R injury was performed on rats, and CKD progression was hastened by unilateral nephrectomy and exposure to 4.0% sodium diet between 35 and 63 days post-I/R. Th17 cells in peripheral blood showed a progressive increase up to 63 days after recovery from I/R injury. Infiltration of leukocytes including Th17 cells was also elevated in bronchiolar lavage (BAL) fluid 7 days after I/R and remained elevated for up to 63 days. Lung histology demonstrated an increase in alveolar cellularity and a significant increase in picrosirius red staining. Suppression of lymphocytes with mycophenolate mofetil (MMF) or an IL-17 antagonist significantly reduced Th17 cell infiltration and fibrosis in lung. In addition, tracheal smooth muscle contraction to acetylcholine was significantly enhanced 63-days after I/R relative to sham-operated controls. These data suggest that AKI is associated with a persistent increase in circulating and lung Th17 cells which may promote pulmonary fibrosis and the potential alteration in airway contractility.en_US
dc.identifier.citationMehrotra, P., Collett, J. A., Gunst, S. J., & Basile, D. P. (2018). Th17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemia. American journal of physiology. Regulatory, integrative and comparative physiology, 314(2), R265–R273. doi:10.1152/ajpregu.00147.2017en_US
dc.identifier.urihttps://hdl.handle.net/1805/20041
dc.language.isoen_USen_US
dc.publisherAmerican Physiological Societyen_US
dc.relation.isversionof10.1152/ajpregu.00147.2017en_US
dc.relation.journalRegulatory, Integrative and Comparative Physiologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectInflammationen_US
dc.subjectIschemia reperfusionen_US
dc.subjectKidneyen_US
dc.subjectLymphocyteen_US
dc.subjectTracheaen_US
dc.titleTh17 cells contribute to pulmonary fibrosis and inflammation during chronic kidney disease progression after acute ischemiaen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867669/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Cardiovascular and Renal Integration Th17 cells contribute to pulmonary fibrosi.pdf
Size:
1.16 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: